Cara Therapeutics Inc (STU:69C)
€ 0.2506 -0.0086 (-3.32%) Market Cap: 14.16 Mil Enterprise Value: -22.43 Mil PE Ratio: 0 PB Ratio: 20.96 GF Score: 31/100

Cara Therapeutics Inc Capital Markets Day Transcript

Feb 16, 2023 / 03:00PM GMT
Release Date Price: €9.68 (+1.62%)
Matthew Murphy

Good morning, and welcome to Cara Therapeutics Capital Markets Day.

Before we begin, let me remind you that today's presentation will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to update or revise the information provided on this webinar as a result of new information or future results or developments.

Participating from Cara Therapeutics today will be Chris Posner, Cara's President and Chief Executive Officer; Dr. Joana Goncalves, Cara's Chief Medical Officer; and Eric Vandal, Cara's Senior Vice President of Commercial. We are also joined by 3 highly accomplished key opinion leaders. First, Dr. Joel Topf is currently an Assistant Clinical Professor of Medicine at the Oakland University William Beaumont School of Medicine,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot